ETPN match-making: Find your last partner for the next EU calls on Nanomedicine
Aug 7, 2025
Dear colleagues, dear members of the European healthtech community, 16 September 2025 is the final deadline for the last wave of Horizon Europe 2025 Health & Mission Cancer calls that matter to Nanomedicine. The European Technology Platform on Nanomedicine (ETPN) organised a 90‑minute flash‑brokerage on 1 August to give “last‑partner seekers” three minutes each to pitch and make instant contacts. Below you’ll find the full expert directory that emerged from the event. Every organisation has opted‑in to be contacted. Scan the call that concerns you, identify the section that fills your missing expertise and reach out right away.
Eligible Horizon Europe calls (Deadline: 16 Sept 2025)
Browse the pitches visually: the lock‑protected public Miro board contains every sticky‑note exactly as shared during the event (no edits). Open the Miro Board
⚠️ Please avoid pasting confidential data onto public comments: the board is view‑only, but the link is public.
Or…Dig our Nanomedicine expert pool & contact list!
Focus: Develop innovative diagnostics, prevention, or therapies for high-burden diseases lacking sufficient research attention, including rare and neglected diseases.
Below is a ready‑to‑use directory of every offer we collected for this call. Names are grouped so that a coordinator can immediately see (i) mature core ideas seeking one last partner, (ii) industrial‑grade manufacturing help, (iii) specialist analytics & disease‑model capabilities, and (iv) broader nano‑delivery know‑how that could reinforce vector‑development or parallel work‑packages.
1 ▪ Cell‑therapy & genomic‑editing core proposals — ready to slot into a consortium
Affiliation · Country
Contact
1‑line fit for the call
National & Kapodistrian University of Athens (Medical School) GR
Thermodynamic profiling of nano‑bio interfaces for Safe‑by‑Design vectors.
These experts did not specify a TOOL‑01‑exclusive angle, but their know‑how frequently underpins engineered‑cell platform work and may fill secondary WPs (vector optimisation, nano‑safety, modelling, etc.).
The directory below groups every offer we received for this call so a coordinator can immediately see (i) mature secretome concepts looking for a slot, (ii) formulation / manufacturing help, (iii) sensing & disease‑model capabilities, and (iv) broader nano‑carrier skills that can reinforce parallel work‑packages.
1 ▪ Secretome / EV therapeutic core proposals — ready to join a consortium
FHNW School of Life Sciences CH – Dr Oya Tagit • oya.tagit@fhnw.ch — polymer/lipid/inorganic theranostics; clinical translation.
University of Cantabria / IDIVAL Hospital ES – Prof. Mónica Fanarraga • fanarrag@unican.es — silica‑NP encapsulation of DNA/ASO payloads; access to tumour biobank samples.
RCSI Dublin – School of Dentistry IE – Dr Shahnawaz Khijmatgar • shahnawazkhijmatgar@rcsi.com — quantum‑dot imaging and RNA‑based regenerative therapies (main focus TOOL‑05 but skills transferrable).
Use these contacts freely — all experts agreed to be approached after the brokerage. One short e‑mail citing TOOL‑02 and this ETPN list is the preferred etiquette.
4) HORIZON‑HLTH‑2025‑01‑TOOL‑03 Generative AI in Biomedical Research (GenAI4EU)
Type: RIA (Research and Innovation Action)
Deadline: 16 September 2025
Budget per project: €15 – 17 million
Total budget: €50 million
Focus: Develop and validate Generative‑AI tools that integrate multimodal biomedical data (omics, imaging, clinical, sensor) to improve research and clinical decision making.
Offers are grouped so a coordinator can immediately see (i) teams already building Gen‑AI / ML platforms, (ii) sensor & data‑pipeline providers, and (iii) formulation or nano‑analytics groups whose ML pipelines could enrich training datasets.
1 ▪ Generative‑AI / ML core platforms — ready to plug into a consortium
Two research groups developing AI pipelines for stroke detection & Parkinson’s monitoring; multimodal sensor streams + digital‑health validation network.
Lab‑/organ‑on‑chip platforms with integrated optical, magnetic and electro‑chemical sensors generating rich, high‑frequency datasets for Gen‑AI training.
LIST – Luxembourg Institute of Science & Technology LU
Nano‑QCM and nano‑patterned sensor surfaces enabling continuous, label‑free molecular‑interaction data streams (ideal for self‑supervised model building).
3 ▪ Formulation / materials groups using ML — valuable training datasets
Physico‑chem & transport datasets on vesicle systems (lung, IPA‑liposomes, polysaccharide carriers); willing to share raw multi‑parametric data for Gen‑AI modelling.
Large annotated datasets from scale‑up runs of polymer/lipid/inorganic theranostic particles; experience aligning process data with clinical endpoints.
4 ▪ Clinical & biobank access (optional WPs)
University Cantabria / IDIVAL Hospital ES – Prof. Mónica Fanarraga • fanarrag@unican.es — oncology biobank samples + nanoparticle gene‑delivery expertise.
IBS Granada – Pneumology Group ES – tvalero@go.ugr.es — patient samples & clinical metadata for respiratory‑disease models.
All contacts opted‑in to be approached. Please reference TOOL‑03 and this ETPN list in your introduction e‑mail.
Focus: Accelerate clinical translation of cutting‑edge biotech solutions including nanomedicine therapies, novel drug‑delivery systems and precision‑medicine approaches.
Below is the full offer pool for this call, clustered so that a coordinator immediately sees (i) translational therapeutic ideas needing partners, (ii) GMP / scale‑up enablers, (iii) analytics & digital‑health support, and (iv) broader nano‑carrier know‑how to reinforce additional work‑packages.
1 ▪ Translational biotech / nanomedicine core proposals — ready to join a consortium
VUT Brno – Faculty of Chemistry CZ – Dr Eliška Bartheldyová • eliska.bartheldyova@fch.vut.cz — Vesicle systems (lung & IPA‑liposomes) + full physico‑chem dataset.
Pneumology Group, IBS Granada ES – tvalero@go.ugr.es — Clinical samples & metadata for respiratory‑focused formulations.
All contacts agreed to be approached. Reference TOOL‑05 and this ETPN list in your first e‑mail for fastest response.
Every offer we collected for this call is clustered so that a coordinator can instantly see (i) GMP‑ready manufacturing partners, (ii) PAT & smart‑manufacturing enablers, (iii) product teams looking for industrial scale‑up, and (iv) wider nano‑carrier / model expertise that can reinforce additional work‑packages.
VUT Brno – Faculty of Chemistry CZ — Dr Eliška Bartheldyová • eliska.bartheldyova@fch.vut.cz — Vesicle systems (lung, IPA‑liposomes) + full physico‑chemical analytics.
FHNW – NanoBiointerfaces CH — Dr Oya Tagit • oya.tagit@fhnw.ch — Scale‑up track‑record for polymer/lipid/inorganic theranostics.
Univ. Bologna – Pharmacy & Biotechnology IT — Dr Giampaolo Zuccheri • giampaolo.zuccheri@unibo.it — 3D cell culture platforms and nanoscale characterisation of drug response.
Pneumology Group, IBS Granada ES — tvalero@go.ugr.es — Clinical respiratory samples for nano‑drug validation.
All contacts agreed to be approached after the brokerage. Mention IND‑01 and this ETPN list in your first e‑mail for the quickest response.
Nanomedicine chemist embedded in a top surgical oncology centre; developing nano‑enabled imaging agents & delivery systems — open to coordinate or join multimodal‑surgery consortia.
Only a handful of participants posted notes specific to this call. We list them all, then flag additional groups (drawn from other oncology calls) that can fill obvious gaps — e.g. nano‑carrier scale‑up or pre‑clinical paediatric tumour models.
3 ▪ Manufacturing & formulation scale‑up (no paediatric note posted, but highly relevant)
CPI – Centre for Process Innovation UK – Claire Hope • claire.hope@uk-cpi.com — GMP RNA‑LNP supply for Phase I; small‑batch flexibility ideal for paediatric trials.
IBI Lorenzini IT – Carlo Khevenhüller • ckhevenhueller@ibi-lorenzini.com — Sterile nano‑drug scale‑up with strong QbD/regulatory support.
Inside Tx (SME) FR – Dr Audrey Nsamela • audrey.nsamela@insidetx.com — Rapid scale‑up of RNA‑LNP/hybrid particles from µL to litres (TRL > 5).
4 ▪ Clinical‑oncology integration & imaging
RCSI – Royal College of Surgeons in Ireland IE – Dr Marco Monopoli • marcomonopoli@rcsi.com — Nanomedicine chemist embedded in paediatric‑surgery hospital network; potential co‑lead on multicentre Phase I/II.
LIST – Luxembourg Institute of Science & Technology LU – Dr Sivashankar Krishnamoorthy • sivashankar.krishnamoorthy@list.lu — Nano‑enabled multimodal sensing & fibre‑optic imaging that can down‑scale for paediatric intra‑op use.
Only the first three organisations posted explicit CANCER‑04 notes; others are suggested matches from adjacent calls to help coordinators assemble a complete paediatric‑trial consortium. All contacts have agreed to be approached — mention CANCER‑04 and this ETPN list in your introductory e‑mail.
IMPORTANT DISCLAIMER This directory is provided by the European Technology Platform on Nanomedicine (ETPN) to facilitate partnership building. It does not constitute an endorsement by the European Commission; ETPN accepts no liability for the accuracy of individual offers. By using the contact details below you agree to treat personal data in compliance with the EU GDPR and with each expert’s own confidentiality requirements.
Kick‑start your consortium!
The ETPN acts as a true *connector*: every day we link project owners, industry and clinicians to accelerate the journey of nanomedicine from lab to patient. Find the expertise you are missing in the directory above, then get in touch (secretariat@etp-nanomedicine.eu); our team will do its best to steer you to the right partners free of charge and share hands‑on tips for building a winning Horizon Europe proposal.
Pro Tip: include the call code and the partner’s name in your email to receive priority matchmaking!
